N-甲酰-间-亮氨酸-丙氨酸-丙氨酸 | 80180-63-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 亮氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-甲酰-间-亮氨酸-丙氨酸-丙氨酸
• 英文名称: N-Formyl-methionyl-leucyl-phenylalanyl-phenylalanine
• 英文别名: (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
• CAS: 80180-63-8
• 化学式: C₃₀H₄₀N₄O₆S
• 分子量: 584.7
• InChiKey: PJENNOWAVBNNNE-CQJMVLFOSA-N

物化性质

• 稳定性/保质期：
  按规定使用和贮存的不会分解，应避碱、酸。

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  41
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  179
• 氢给体数：
  5
• 氢受体数：
  7

安全信息

• WGK Germany：
  3

文献信息

• METHOD FOR INTEGRIN LIGAND DISCOVERY
  申请人：Chigaev Alexandre

  公开号：US20130005782A1

  公开（公告）日：2013-01-03

  This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery base upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angiogenesis and/or anti-thrombotic agents and for the treatment of integrin mediated diseases and/or conditions.
• NITRIC OXIDE/cGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION
  申请人：STC.UNM

  公开号：US20140088034A1

  公开（公告）日：2014-03-27

  The invention provides methods of treating nitric oxide/cGMP pathway-cell adhesion disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention relates to a method for down-regulating α 4 β 1 -integrin affinity and inhibiting and reversing adhesion formation in patients or subjects in need using a nitric oxide donor.
• US8911952B2
  申请人：——

  公开号：US8911952B2

  公开（公告）日：2014-12-16
• [EN] METHOD FOR INTEGRIN LIGAND DISCOVERY<br/>[FR] PROCÉDÉ DE DÉCOUVERTE DE LIGANDS DE L'INTÉGRINE
  申请人：STC UNM

  公开号：WO2011119732A2

  公开（公告）日：2011-09-29

  This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery base upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angiogenesis and/or anti-thrombotic agents and for the treatment of integrin mediated diseases and/or conditions.
• [EN] NITRIC OXIDE/CGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION<br/>[FR] INHIBITION DE LA VOIE DE L'OXYDE NITRIQUE/CGMP D'ADHÉSION CELLULAIRE SE RAPPORTANT À VLA-4
  申请人：STC UNM

  公开号：WO2012154975A2

  公开（公告）日：2012-11-15

  The invention provides methods of treating nitric oxide/cGMP pathway-cell adhesion disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention relates to a method for down-regulating α4β1-integrin affinity and inhibiting and reversing adhesion formation in patients or subjects in need using a nitric oxide donor.